1. Home
  2. RNTX vs GIFT Comparison

RNTX vs GIFT Comparison

Compare RNTX & GIFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNTX
  • GIFT
  • Stock Information
  • Founded
  • RNTX 2001
  • GIFT 1999
  • Country
  • RNTX United States
  • GIFT United States
  • Employees
  • RNTX 11
  • GIFT N/A
  • Industry
  • RNTX Biotechnology: Pharmaceutical Preparations
  • GIFT Catalog/Specialty Distribution
  • Sector
  • RNTX Health Care
  • GIFT Consumer Discretionary
  • Exchange
  • RNTX Nasdaq
  • GIFT Nasdaq
  • Market Cap
  • RNTX 34.6M
  • GIFT 33.9M
  • IPO Year
  • RNTX N/A
  • GIFT N/A
  • Fundamental
  • Price
  • RNTX $1.39
  • GIFT N/A
  • Analyst Decision
  • RNTX Buy
  • GIFT Strong Buy
  • Analyst Count
  • RNTX 2
  • GIFT 1
  • Target Price
  • RNTX $10.00
  • GIFT $4.00
  • AVG Volume (30 Days)
  • RNTX 251.4K
  • GIFT 21.9K
  • Earning Date
  • RNTX 11-13-2025
  • GIFT 11-12-2025
  • Dividend Yield
  • RNTX N/A
  • GIFT N/A
  • EPS Growth
  • RNTX N/A
  • GIFT N/A
  • EPS
  • RNTX N/A
  • GIFT N/A
  • Revenue
  • RNTX N/A
  • GIFT $90,569,384.00
  • Revenue This Year
  • RNTX N/A
  • GIFT $5.90
  • Revenue Next Year
  • RNTX N/A
  • GIFT $13.45
  • P/E Ratio
  • RNTX N/A
  • GIFT N/A
  • Revenue Growth
  • RNTX N/A
  • GIFT 8.55
  • 52 Week Low
  • RNTX $1.04
  • GIFT $0.82
  • 52 Week High
  • RNTX $4.40
  • GIFT $2.38
  • Technical
  • Relative Strength Index (RSI)
  • RNTX 61.54
  • GIFT N/A
  • Support Level
  • RNTX $1.13
  • GIFT N/A
  • Resistance Level
  • RNTX $1.57
  • GIFT N/A
  • Average True Range (ATR)
  • RNTX 0.10
  • GIFT 0.00
  • MACD
  • RNTX 0.03
  • GIFT 0.00
  • Stochastic Oscillator
  • RNTX 62.22
  • GIFT 0.00

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

About GIFT RDE Inc. Common Stock

Giftify Inc through its wholly-owned subsidiary, has been in the business of connecting digital consumers, businesses and communities with dining and merchant deal options throughout the United States. The company connects digital consumers, businesses, and communities offering dining and merchant deal options nationwide restaurants, and retailers to customers. The Company buys merchant gift cards from the general public and distributors at a discount and then resells them at a markup.

Share on Social Networks: